Skip to content

A phase III study of Actos combination drug in diabetic patients

-

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220870
Enrollment
Unknown
Registered
2009-09-24
Start date
2009-09-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus

Interventions

investigational material(s) Generic name etc : Actos combination drug INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigation

Sponsors

Takeda Pharmaceutical Company Limited
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Admission status: Outpatient 2.The subject who applies for participation in this study and is capable of giving written informed consent, reading informed consent form and other study-related documents, and understanding them, etc.

Exclusion criteria

Exclusion criteria: 1.The subject with serious cardiac disease, cerebrovascular disease, or serious pancreatic or hematological disease. 2.The subject is considered ineligible to participate in the study by the investigator or subinvestigator, etc.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026